Publishing of Orion Corporation's Financial Statement Release for 2018 on 6 February 2019

ORION CORPORATION                    PRESS RELEASE                   23 JANUARY 2019 at 13.30 EET 

Publishing of Orion Corporation's Financial Statement Release for 2018 on 6 February 2019

Orion will publish its Financial Statement Release for 2018 on Wednesday, 6 February 2019 approximately at 12.00 noon Finnish time (EET). The release and related presentation material in Finnish and in English will be available on the Group's homepage at www.orion.fi/investors promptly after the publishing.

News conference for analysts and media

A news conference for analysts and media will be held on Wednesday, 6 February 2019 at 13.30 EET at Orion's head office, address Orionintie 1A, 02200 Espoo. President and CEO Timo Lappalainen will give a brief presentation in English on the financial review. Questions can be asked after the presentation also via conference call. Participants should be prepared to present a photo ID.

Live webcast and conference call

A link to the live webcast will be available on Orion's website at www.orion.fi/investors.
The conference call ID is 685819 and the phone numbers to participate the conference are:

Finland: [phone]
Sweden: [phone]
UK: [phone]
USA: [phone]

News conference recordings

A recording of the event in English and a recording of the presentation by the President and CEO in Finnish will be available on Orion's website later the same day.

Silent period

The silent period preceding the publication is ongoing and continues until the disclosure.


Contact person:            
                                                            
Lilli Riikonen, Communications Manager,  tel. [phone] 

Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo
Homepage: www.orion.fi/en

Orion is a globally operating Finnish pharmaceutical company - a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion's pharmaceutical R&D are central nervous system (CNS) disorders, oncology and respiratory diseases for which Orion develops inhaled Easyhaler pulmonary drugs. Orion's net sales in 2017 amounted to EUR 1,034 million and the company had about 3,200 employees. Orion's A and B shares are listed on Nasdaq Helsinki.

---

This announcement is distributed by West Corporation on behalf of West Corporation clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Orion Oyj via Globenewswire